Dani Fribourg
Pulmonary Disease · Farmington Hills, MINPI 1134575798
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by United Therapeutics Corporation at 48.5% of the total. 2025 is the largest year on record at $8,900, more than ten times the $399 reported in 2019.
Across 270 payments — averaging $51.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$7K
- GSK$1K
- AstraZeneca$1K
- Inari Medical, Inc.$624
- Bayer$492
- Actelion Pharmaceuticals US, Inc.$434
- plus $3K from 29 others
What the payments were for
- Consulting fees$5,50039%
- Travel & lodging$6995%
- Food & beverage$7,60754%
- Education$1801%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 31 | $6,778 |
| GSK | 55 | $1,256 |
| AstraZeneca | 38 | $1,089 |
| Inari Medical, Inc. | 5 | $624 |
| Bayer | 14 | $492 |
| Actelion Pharmaceuticals US, Inc. | 13 | $434 |
| Regeneron Healthcare Solutions, Inc. | 21 | $429 |
| Sanofi | 9 | $315 |
| Mylan Specialty L.p. | 11 | $271 |
| Pulmonx Corporation | 3 | $259 |
| Grifols USA, LLC | 6 | $252 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $239 |
| Insmed, Inc. | 11 | $193 |
| Inspire Medical Systems, Inc. | 4 | $164 |
| Merck | 7 | $144 |
| Mallinckrodt Enterprises LLC | 3 | $126 |
| Stryker | 1 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Viatris Specialty LLC | 3 | $79 |
| Axsome Therapeutics, Inc. | 4 | $76 |
| Electromed, Inc. | 6 | $73 |
| Mallinckrodt Hospital Products Inc. | 3 | $64 |
| Intuitive Surgical | 1 | $63 |
| Gilead | 3 | $41 |
| Jazz Pharmaceuticals Inc. | 2 | $41 |
| Philips North America LLC | 2 | $40 |
| Boehringer Ingelheim | 1 | $34 |
| Baxter Healthcare | 1 | $32 |
| Lungpacer Medical USA Inc | 1 | $31 |
| Circassia Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Amgen | 1 | $26 |
| Edwards Lifesciences | 1 | $23 |
| Vapotherm Inc | 1 | $16 |
| CSL Behring | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYVASO$6,020
- NUCALA$775
- FLOWTRIEVER CATHETER, S$552
- CT THROMBECTOMY SYSTEM KIT$552
- BREZTRI$250
- Adempas$200
- LUMRYZ$200
- CHARTIS CATHETER$156
- ZEPHYR DELIVERY CATHETER$156
- ZEPHYR ENDOBRONCHIAL VALVE$156
- PULMONX CHARTIS TABLET CONSOLE$156
- Prolastin-C Liquid$155
- UPTRAVI$125
- OPSUMIT$125
- Inspire$111
- CLOTTRIEVER BOLD CATHETER$105
How this compares
$13,986 in reported general payments places this provider in the 85th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 20 | $273,242 |
| Tyvaso DpiTreprostinil | 11 | $265,039 |
| OpsumitMacitentan | 19 | $239,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $68,625 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 61 | $52,206 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,632 |
| Montelukast Sodium | 42 | $563 |
| Azithromycin | 20 | $240 |
| Prednisone | 31 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $492 | $273,24220 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $434 | $239,84519 claims |
| GSKTrelegy Ellipta | $1,256 | $68,62586 claims |
| AstraZenecaBreztri Aerosphere | $1,089 | $52,20661 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Farmington Hills
- Muhammad EhteshamFarmington Hills$21K
- Irina ShanidzeFarmington Hills$20K
- Mohammed FarraFarmington Hills$20K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.